Table 1.

Baseline of characteristics of the included trials

Source		Number of patents	Age	Male	Diabetes	Diameter stenosis (%)	Vessel diameter (mm)	Lesion length (mm)	Inclusion criteria	Exclusion criteria	Primary outcomes	Secondary outcomes	Other outcomes	Follow-up duration, year	Funding
SPIRIT II [45–47]	EES*	223	62 ± 10	158	51	61 ± 12	2.70 ± 0.52	13.0 ± 5.7	1. Ischemia and vessel size 2.5–4.25 mm and lesion length ≤ 28 mm; 2. A percentage diameter stenosis (DS) 50 %−99 %	1. Recent MI‡,LVEFx ≤ 30 %; 2. LM§ heavily calcified lesion; 3. Visible thrombus	.MI‡ ST††	ID-TLR# ID-MACEll	CABG**	3.4,5	Abbott vascular
	PES†	77	62 ± 9	61	20	59 ± 10	2.82 ± 0.58	13.2 ± 6.4
SPIRIT III [48, 49]	EES*	669	63.2 ± 10.5	469	198	70.0 ± 13.3	2.77 ± 0.45	14.7 ± 5.6	1. Stable, unstable angina; 2. Ischemia with vessel size 2.5–3.75 mm and lesion length ≤ 28 mm	1. Recent MI‡,LVEFx < 30 %; 2. LM§ bifurcation; 3. BG; 4. Calcification; 5. Thrombus	MAGE‡‡ Cardiac death MI‡ ST††	TLRxx TVR§§	TLFllll	3.5	Abbott vascular
	PES†	332	62.8 ± 10.2	218	92	69.4 ± 13.6	2.76 ± 0.46	14.7 ± 5.7
SPIRIT IV [50]	EES*	2460	63.3 ± 10.5	1664	787	72.3 ± 12.6	—	—	1. Stable, unstable angina; 2. Ischemia with vessel size 2.5–4.25 mm and lesion length ≤ 28 mm	1. Recent MI‡,LVEFx < 30 %; 2. LM§ bifurcation; 3. lcomplex lesions; 4. Totally occluded vessels; 5. Large bifurcations; 6. Excessive calcification; 7. Tortuosity; 8. Angulation; 9. Thrombus	MAGE‡‡ Cardiac death MI‡ .ST††	TLRxx ID-TLR#	TLFllll	3	Abbott vascular
	PES†	1230	63.3 ± 10.2	833	399	72.0 ± 12.8	—	—

Abbreviations: ^*:everolimus-eluting stent; ^†:paclitaxel-eluting stent; ^‡:myocardial infarction; ^xLVEF: left ventricular ejection fraction; ^§:left main; ^ll:major adverse cardiac events; ^#:ischemia-driven target lesion revascularization; ^**:coronary artery bypass graft; ^††:sent thrombus ; ^‡‡ :major adverse cardiac events; ^xx:target lesion revascularization; ^§§:target vessel revascularization; ^llll:Target lesion failure